1 / 6

Oncologische interventieradiologie - De toekomst?

4 D ’ s 7 februari 2014, Doorn. Oncologische interventieradiologie - De toekomst?. Otto van Delden Radiologie AMC Amsterdam. Wat is oncologische interventieradiologie?. Complicaties behandelen Tumorbehandeling mogelijk maken Invasieve beeldgeleide diagnostiek Tumorablaties

aiden
Download Presentation

Oncologische interventieradiologie - De toekomst?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 4 D’s 7 februari 2014, Doorn Oncologische interventieradiologie - De toekomst? Otto van Delden Radiologie AMC Amsterdam

  2. Wat is oncologische interventieradiologie? • Complicaties behandelen • Tumorbehandeling mogelijk maken • Invasieve beeldgeleide diagnostiek • Tumorablaties • Tumorembolisaties • Inwendige tumorbestraling • Lokale “drug delivery”

  3. Wat is oncologische interventieradiologie? • Tumorablaties (RFA, MWA, IEP (irreversibele electroporese), HIFU) • Tumorembolisaties (“bland”, TACE) • Inwendige tumorbestraling (SIRT (selective internal radiotherapy)) • Lokale “drug delivery” (i.a. delivery, “micro-bubbles”) • Vena portae embolisatie

  4. Welke tumoren? • Primaire levertumoren (HCC, Cholangioca.) • Levermetastasen (colorectaal (CRLM’s), NET (neuro-endocrien), andere GE-tumoren) • Pancreastumoren • Galwegtumoren • Long- en skeletmetastasen

  5. Toekomst oncologische interventieradiologie? • Verbetering techniek • Betere planning, beeldgeleiding, positionering • Outcome evaluatie / betere studies • Opleiding / professionalisering

  6. Welke studies nu doen? • Rol RFA / MWA bij CRLM’s (RFA vs resectie voor kleine CRLM’s, RFA vs resectie voor HCC) • Rol IEP (irresectabel pancreascarcinoom) • Rol SIRT (SIRT vs embo. NET, SIRT vs TACE HCC, SIRT vs syst. behandeling HCC, SIRT vs syst. behandeling CRC)

More Related